Mortality outcomes in individuals with MASLD <i>versus</i> MASLD and increased alcohol intake

Simple item page
dc.contributor.authorAboona, Majd B.
dc.contributor.authorDanpanichkul, Pojsakorn
dc.contributor.authorChen, Vincent L.
dc.contributor.authorRangan, Pooja
dc.contributor.authorKim, Donghee
dc.contributor.authorAlkhouri, Naim
dc.contributor.authorFallon, Michael B.
dc.contributor.authorNoureddin, Mazen
dc.contributor.authorArab, Juan Pablo
dc.contributor.authorWijarnpreecha, Karn
dc.date.accessioned2025-01-20T16:10:25Z
dc.date.available2025-01-20T16:10:25Z
dc.date.issued2024
dc.description.abstractBackground and Aim Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a leading cause of chronic liver disease worldwide. A new entity termed MetALD has also been described and is defined as individuals with MASLD and increased alcohol intake. However, the natural history of MetALD compared with MASLD is unknown. We aimed to compare longitudinal outcomes in patients with MASLD versus MetALD. Methods This study was performed using data from the National Health and Nutrition Examination Survey from 2011 to 2018. MASLD patients (defined by the United States Fatty Liver Index > 30) who met cardiometabolic criteria including body mass index (BMI) > 25 (BMI > 23 in Asians), hypertension, diabetes mellitus, dyslipidemia, and hypertriglyceridemia were included. MetALD was defined as MASLD with increased alcohol intake (3-6 standard drinks per day in males; 2-5 standard drinks per day in females). A comparison of overall, cardiovascular, cancer-related, and other causes of mortality in patients with MASLD versus MetALD was performed. Results A total of 2838 individuals with MASLD and 2557 individuals with MetALD were included with a median follow-up time of 56 months. MetALD patients were at increased risk of cancer-related mortality compared with patients with MASLD (hazard ratio 1.32; 95% confidence interval 1.14-1.53; P < 0.01). However, there was no significant difference in overall, cardiovascular, and other causes of mortality. Conclusions Patients with MetALD were at higher risk for cancer-related mortality than MASLD. Close attention to regular cancer surveillance and accurate classification of alcohol consumption in individuals with diagnosed MASLD is warranted to help improve patient care and outcome.
dc.description.funderNIDDK
dc.fuente.origenWOS
dc.identifier.doi10.1111/jgh.16726
dc.identifier.eissn1440-1746
dc.identifier.issn0815-9319
dc.identifier.urihttps://doi.org/10.1111/jgh.16726
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/90211
dc.identifier.wosidWOS:001296461800001
dc.language.isoen
dc.revistaJournal of gastroenterology and hepatology
dc.rightsacceso restringido
dc.subjectAlcohol use
dc.subjectCancer
dc.subjectMortality
dc.subjectNHANES
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleMortality outcomes in individuals with MASLD <i>versus</i> MASLD and increased alcohol intake
dc.typeartículo
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas